<DOC>
	<DOCNO>NCT02090283</DOCNO>
	<brief_summary>The purpose study assess continue safety topical use SD-101 cream ( 6 % ) subject Epidermolysis Bullosa `` Funding-Source-FDA OOPD ''</brief_summary>
	<brief_title>Open Label Extension Study Evaluate Safety SD-101 Cream Subjects With Epidermolysis Bullosa</brief_title>
	<detailed_description>Epidermolysis Bullosa ( EB ) rare group inherit disorder manifest blister erosion skin case , epithelial lining organ , response little apparent trama . There lack effective agent skin disorder involve blister lesion formation . Current approve therapy minimally effective safety issue . Scioderm develop SD-101 Dermal Cream ( 6 % ) treatment EB . This open label extension study ass continue safety topically apply SD-101 Dermal Cream ( 6 % ) subject Simplex , Recessive Dystrophic , Junctional non-Herlitz Epidermolysis Bullosa . SD-101 Dermal Cream ( 6 % ) apply topically , day entire body period 1080 day . Subjects successfully complete entire SD-003 study option roll SD-004 study . The baseline visit 1 occur final visit date SD-003 . The Body Surface Area ( BSA ) coverage blister lesion assessment make final SD-003 study visit use baseline information visit 1 SD-004 study . The subject return study site visit 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ( 14 , 90 , 180 , 270 , 360 , 450 , 630 , 720 , 810 , 900 , 990 , 1080 day respectively ) BSA assess . For female subject childbearing potential , urine pregnancy test perform visit 4 , 6 , 8 , 10 , 12 14 .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>Informed consent form sign subject subject 's legal representative ; subject age 18 capable provide assent , sign assent subject . Subject ( caretaker ) must willing comply protocol requirement . Subject must successfully complete SD003 study . Subjects meet inclusion criterion . Pregnancy breastfeed study . ( A urine pregnancy test perform final visit SD003 female subject childbearing potential ) Females childbearing potential abstinent practice medically acceptable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Epidermolysis Bullosa</keyword>
	<keyword>Simplex</keyword>
	<keyword>Recessive Dystrophic</keyword>
	<keyword>Junctional non-Herlitz</keyword>
</DOC>